Research
Hormonal
Long-term use of semaglutide (GLP-1 RA) may be associated with the development of exocrine pancreatic insufficiency, particularly in patients with concurrent chronic alcohol consumption.
If you are taking semaglutide or similar GLP-1 medications, be aware of potential pancreatic issues, especially if you drink alcohol. Report symptoms like fatty stools (steatorrhea) or abdominal pain immediately. Your doctor should monitor your lipase levels regularly.
WeakQualifiesVERY_LOW confidence
The course of our case suggests a potential association between semaglutide and chronic alcohol consumption in the development of exogenous pancreatic insufficiency.
Why this rating
Based on a single case report (n=1), not generalizable.
Source
Exocrine Pancreatic Insufficiency During the Use of Semaglutide: A Case Report
Clivaldo Agra de Melo et al. · Cureus · 2024
DOI 10.7759/cureus.55549
case_report · n=1Cited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →